amsacrine has been researched along with Recrudescence in 37 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two handred and ninty-one patients with acute leukemias, including initial, relapsed and refractory cases, were treated with regimens combining the amsacrine with other antileukemic drugs." | 9.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 7.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 7.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "Two handred and ninty-one patients with acute leukemias, including initial, relapsed and refractory cases, were treated with regimens combining the amsacrine with other antileukemic drugs." | 5.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 3.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 3.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "Strategies to reduce recurrence are urgently required." | 3.01 | Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021) |
| "Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history." | 2.80 | Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. ( Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K, 2015) |
| "In all, 625 patients with acute lymphoblastic leukemia (ALL) entered the Leucémie Aiguë Lymphoblastique de l'Adulte-94 trial from June 1994 to June 1999, and received a 4-week induction therapy followed either by chemotherapy alone or stem cell transplantation (SCT)." | 2.71 | Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia. ( Boiron, JM; Buzyn, A; Delannoy, A; Fegueux, N; Fière, D; Gardin, C; Georges, M; Hacini, M; Huguet, F; Kuentz, M; Lhéritier, V; Micléa, JM; Reman, O; Stamatoullas, A; Thomas, X; Vernant, JP, 2004) |
| "At ABMT, 17 patients were in untreated relapse and one was in third complete remission (CR)." | 2.68 | Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. ( Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA, 1996) |
| "5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia." | 2.68 | A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). ( Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997) |
| "FLAG-amsacrine was an effective bridge to allogeneic transplant with 38% successfully transplanted with excellent outcomes (median OS not reached)." | 1.39 | Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. ( Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A, 2013) |
| " The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future." | 1.30 | In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. ( Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999) |
| "The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy." | 1.29 | Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. ( Welborn, JL, 1994) |
| "Ten patients with acute myeloblastic leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (ara-C, 3 g/m2/12 hours x 4) and amsacrine (150 mg/m2/day x 5)." | 1.29 | Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. ( Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J, 1993) |
| " push in a dosage of 150 mg/m2 for 5 days." | 1.27 | 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. ( Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983) |
| "27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA." | 1.27 | AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia. ( Boccia, R; Champlin, RE; Gale, RP; Kim, CC; Zighelboim, J, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.03) | 18.7374 |
| 1990's | 19 (51.35) | 18.2507 |
| 2000's | 4 (10.81) | 29.6817 |
| 2010's | 2 (5.41) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Meur, GL | 1 |
| Plesa, A | 1 |
| Larcher, MV | 1 |
| Fossard, G | 1 |
| Barraco, F | 1 |
| Loron, S | 1 |
| Balsat, M | 1 |
| Ducastelle-Leprêtre, S | 1 |
| Gilis, L | 1 |
| Thomas, X | 2 |
| Ghesquières, H | 1 |
| Tigaud, I | 1 |
| Hayette, S | 1 |
| Huet, S | 1 |
| Sujobert, P | 1 |
| Renault, M | 1 |
| Thérèse, RM | 1 |
| Michallet, M | 1 |
| Labussière-Wallet, H | 1 |
| Heiblig, M | 1 |
| Craddock, C | 1 |
| Jackson, A | 1 |
| Loke, J | 1 |
| Siddique, S | 1 |
| Hodgkinson, A | 1 |
| Mason, J | 1 |
| Andrew, G | 1 |
| Nagra, S | 1 |
| Malladi, R | 1 |
| Peniket, A | 1 |
| Gilleece, M | 1 |
| Salim, R | 1 |
| Tholouli, E | 1 |
| Potter, V | 1 |
| Crawley, C | 1 |
| Wheatley, K | 2 |
| Protheroe, R | 1 |
| Vyas, P | 1 |
| Hunter, A | 1 |
| Parker, A | 1 |
| Wilson, K | 1 |
| Pavlu, J | 1 |
| Byrne, J | 1 |
| Dillon, R | 1 |
| Khan, N | 1 |
| McCarthy, N | 1 |
| Freeman, SD | 1 |
| Cortes, JE | 1 |
| Goldberg, SL | 1 |
| Feldman, EJ | 2 |
| Rizzeri, DA | 1 |
| Hogge, DE | 1 |
| Larson, M | 1 |
| Pigneux, A | 1 |
| Recher, C | 1 |
| Schiller, G | 1 |
| Warzocha, K | 1 |
| Kantarjian, H | 1 |
| Louie, AC | 1 |
| Kolitz, JE | 1 |
| Zohren, F | 1 |
| Czibere, A | 1 |
| Bruns, I | 1 |
| Fenk, R | 1 |
| Schroeder, T | 1 |
| Gräf, T | 1 |
| Haas, R | 1 |
| Kobbe, G | 1 |
| Fong, CY | 1 |
| Grigoriadis, G | 1 |
| Hocking, J | 1 |
| Coutsouvelis, J | 1 |
| Muirhead, J | 1 |
| Campbell, P | 1 |
| Paul, E | 1 |
| Walker, P | 1 |
| Avery, S | 1 |
| Patil, S | 1 |
| Spencer, A | 1 |
| Schwarer, A | 1 |
| Wei, A | 1 |
| Locatelli, F | 2 |
| Labopin, M | 1 |
| Ortega, J | 1 |
| Meloni, G | 1 |
| Dini, G | 1 |
| Messina, C | 1 |
| Yaniv, I | 1 |
| Fagioli, F | 1 |
| Castel, V | 1 |
| Shaw, PJ | 1 |
| Ferrant, A | 1 |
| Pession, A | 1 |
| Sociè, G | 1 |
| Frassoni, F | 1 |
| Reman, O | 1 |
| Buzyn, A | 1 |
| Lhéritier, V | 1 |
| Huguet, F | 1 |
| Kuentz, M | 1 |
| Stamatoullas, A | 1 |
| Delannoy, A | 1 |
| Fegueux, N | 1 |
| Micléa, JM | 1 |
| Boiron, JM | 2 |
| Vernant, JP | 1 |
| Gardin, C | 1 |
| Hacini, M | 1 |
| Georges, M | 1 |
| Fière, D | 1 |
| Cabanillas, F | 1 |
| Kahn, SB | 1 |
| Sklaroff, R | 1 |
| Lebedda, J | 1 |
| Conroy, JF | 1 |
| Bulova, S | 1 |
| Brodsky, I | 1 |
| Obrecht, JP | 1 |
| Hines, JD | 1 |
| Oken, MM | 2 |
| Mazza, JJ | 1 |
| Keller, AM | 1 |
| Streeter, RR | 1 |
| Glick, JH | 2 |
| Cassileth, PA | 1 |
| Lyman, GH | 1 |
| Bennett, JM | 1 |
| Boccia, R | 1 |
| Zighelboim, J | 1 |
| Champlin, RE | 1 |
| Kim, CC | 1 |
| Gale, RP | 1 |
| Case, DC | 1 |
| Willemze, R | 3 |
| Archimbaud, E | 2 |
| Muus, P | 2 |
| Welborn, JL | 1 |
| Ghaddar, HM | 1 |
| Plunkett, W | 1 |
| Kantarjian, HM | 2 |
| Pierce, S | 1 |
| Freireich, EJ | 2 |
| Keating, MJ | 2 |
| Estey, EH | 1 |
| Puntous, M | 1 |
| Lacombe, F | 1 |
| Dumain, P | 1 |
| Marit, G | 1 |
| Cony-Makhoul, P | 1 |
| Belloc, F | 1 |
| Laurent, G | 1 |
| Bernard, P | 1 |
| Reiffers, J | 1 |
| Delmer, A | 1 |
| Marie, JP | 1 |
| Thevenin, D | 1 |
| Suberville, AM | 1 |
| Zittoun, R | 2 |
| Jehn, U | 2 |
| Heinemann, V | 1 |
| Klumper, E | 1 |
| Ossenkoppele, GJ | 1 |
| Pieters, R | 1 |
| Huismans, DR | 1 |
| Loonen, AH | 1 |
| Rottier, A | 1 |
| Westra, G | 1 |
| Veerman, AJ | 1 |
| de la Rubia, J | 1 |
| Sanz, GF | 1 |
| Martín, G | 1 |
| Sempere, A | 1 |
| Picón, I | 1 |
| Carral, A | 1 |
| Larrea, L | 1 |
| Martínez, J | 1 |
| Soler, MA | 1 |
| Bonanad, S | 1 |
| López, F | 1 |
| Jarque, I | 1 |
| Sanz, MA | 1 |
| de Nully Brown, P | 1 |
| Hoffmann, T | 1 |
| Hansen, OP | 1 |
| Boesen, AM | 1 |
| Grønbaek, K | 1 |
| Hippe, E | 1 |
| Jensen, MK | 1 |
| Thorling, K | 1 |
| Storm, HH | 1 |
| Pedersen-Bjergaard, J | 1 |
| Suciu, S | 1 |
| Stryckmans, P | 1 |
| Louwagie, EA | 1 |
| Berneman, Z | 1 |
| Tjean, M | 1 |
| Wijermans, P | 1 |
| Dohner, H | 1 |
| Labar, B | 1 |
| Jaksic, B | 1 |
| Dardenne, M | 1 |
| Maurer, LH | 1 |
| Herndon, JE | 1 |
| Hollis, DR | 1 |
| Aisner, J | 1 |
| Carey, RW | 1 |
| Skarin, AT | 1 |
| Perry, MC | 1 |
| Eaton, WL | 1 |
| Zacharski, LL | 1 |
| Hammond, S | 1 |
| Green, MR | 1 |
| Stevens, RF | 1 |
| Hann, IM | 1 |
| Gray, RG | 1 |
| Ozkaynak, MF | 1 |
| Avramis, VI | 1 |
| Carcich, S | 1 |
| Ortega, JA | 1 |
| Lönnerholm, G | 1 |
| Frost, BM | 1 |
| Larsson, R | 1 |
| Liliemark, E | 1 |
| Nygren, P | 1 |
| Peterson, C | 1 |
| Perel, Y | 1 |
| Auvrignon, A | 1 |
| Leblanc, T | 1 |
| Vannier, JP | 1 |
| Michel, G | 1 |
| Nelken, B | 1 |
| Gandemer, V | 1 |
| Schmitt, C | 1 |
| Lamagnere, JP | 1 |
| De Lumley, L | 1 |
| Bader-Meunier, B | 1 |
| Couillaud, G | 1 |
| Schaison, G | 1 |
| Landman-Parker, J | 1 |
| Thuret, I | 1 |
| Dalle, JH | 1 |
| Baruchel, A | 1 |
| Leverger, G | 1 |
| Evensen, SA | 1 |
| Brinch, L | 1 |
| Stavem, P | 1 |
| Tjønnfjord, G | 1 |
| Bernasconi, C | 1 |
| Lazzarino, M | 1 |
| Morra, E | 1 |
| Alessandrino, EP | 1 |
| Pagnucco, G | 1 |
| Resegotti, L | 1 |
| Ficarra, F | 1 |
| Bacigalupo, A | 1 |
| Carella, AM | 1 |
| Richel, DJ | 1 |
| Colly, LP | 1 |
| Kluin-Nelemans, JC | 1 |
| Arlin, ZA | 1 |
| Mittelman, A | 1 |
| Ahmed, T | 1 |
| Puccio, C | 1 |
| Chun, HG | 1 |
| Cook, P | 1 |
| Baskind, P | 1 |
| Marboe, C | 1 |
| Mehta, R | 1 |
| Wahlin, A | 1 |
| Estey, E | 1 |
| Walters, R | 1 |
| Smith, T | 1 |
| McCredie, KB | 1 |
| Liang, R | 1 |
| Chan, TK | 1 |
| Todd, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial[NCT05628623] | Phase 2 | 184 participants (Anticipated) | Interventional | 2023-10-23 | Not yet recruiting | ||
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162] | Phase 3 | 580 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 trials available for amsacrine and Recrudescence
| Article | Year |
|---|---|
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi | 2021 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Fr | 2009 |
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2004 |
[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Child, Preschool; Female; Humans; Leukemia; Male; Middle | 1997 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubici | 1981 |
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1994 |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug | 1993 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined | 1997 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1997 |
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 1997 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1998 |
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation | 2002 |
Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1992 |
22 other studies available for amsacrine and Recrudescence
| Article | Year |
|---|---|
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fema | 2013 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Ther | 1983 |
[Treatment of acute myeloid leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; | 1984 |
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1984 |
High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Sc | 1984 |
AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
Topics: Aminoacridines; Amsacrine; Drug Evaluation; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Recur | 1984 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; F | 1993 |
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Aspartate-Ammonia Ligase; Clinical | 1994 |
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Mar | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Et | 1993 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine | 1996 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1998 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxor | 1999 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy | 1992 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemot | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M | 1991 |
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1989 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubi | 1987 |
Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1988 |